IMMUNICON ANNOUNCES RECEIPT BY VERIDEX OF ADDITIONAL

Immunicon Corporation announced today that it has been informed by Veridex, a Johnson & Johnson company, that Veridex has received clearance from the U.S. Food and Drug Administration (FDA) of a pre-market notification, or 510(k), regulatory submission in which Veridex provided additional data from Immunicon's clinical trial in metastatic breast cancer for inclusion in the package insert of the CellSearch Circulating Tumor Cell (CTC) Kit. These data, related to the relationship between CTCs and progression free survival and overall survival at additional time points during therapy, were presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in May.
Yahoo News